PF-06940434

N/A

Report date: 2026/03/20 20:03:07

Base Information

Drug NamePF-06940434
Drug Alias NamePF-06940434
ClassificationBiologics
Mechanisms of ActionIntegrin alpha-V antagonists
TargetsIntegrin alpha-V
Therapy Area/IndicationsNeoplasm MetastasisEndometrial NeoplasmsOvarian Neoplasms +[12
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSlovakiaTaiwan +[6
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsNeoplasm Metastasis
Inactive IndicationsEndometrial NeoplasmsOvarian NeoplasmsPancreatic Neoplasms +[11

Other Information

ATC CodeN/A
Related LinksN/A